Core Insights - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable emphasis on quality improvement amidst a deep industry adjustment [1][2]. Group 1: Industry Performance - In the first half of 2025, retail sales of cosmetics in China increased by 2.9% year-on-year, with domestic brands capturing over 55% market share [2]. - Exports of cosmetics surged by 12% to 25.8 billion yuan, indicating strong overseas growth potential [2]. Group 2: Leading Companies - Leading companies like Proya, Mao Geping, and Shangmei continue to excel, while others like Huaxi Biological and Fulejia are lagging behind [2]. - Proya reported revenue of 5.362 billion yuan, a 7.21% increase, and a net profit of 799 million yuan, up 13.8% [4]. - Mao Geping achieved a revenue of 2.588 billion yuan, with a remarkable growth rate of 31.3%, and a net profit of 670 million yuan, reflecting a 36.1% increase [5]. - Shangmei's revenue reached 4.108 billion yuan, growing by 17.3%, with a net profit of 556 million yuan, up 34.7% [5]. - Juzhi Biological reported revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2% [5]. Group 3: Underperforming Companies - Huaxi Biological reported a significant decline, with revenue dropping nearly 19.57% to 2.261 billion yuan and net profit falling 35.38% to 221 million yuan [6]. - Fulejia's revenue decreased by 8.15% to 863 million yuan, with a net profit decline of 32.54% to 230 million yuan, largely due to increased marketing expenses [9][11]. Group 4: Second-Tier Companies - Second-tier companies like Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13]. - Shanghai Jahwa's revenue was 3.478 billion yuan, up 4.8%, with a net profit of 270 million yuan, increasing by 11.7% [14]. - Marubi achieved revenue of 1.769 billion yuan, a 30.83% increase, but net profit growth was only 5.21% [14]. - Shuiyang reported revenue of 2.5 billion yuan, a 9.02% increase, and a net profit of 123 million yuan, up 16.54% [14].

Core Viewpoint - The beauty industry in China is experiencing a significant performance divergence among leading companies, with a notable increase in quality, as evidenced by the half-year reports of domestic beauty brands [2]. Group 1: Leading Companies Performance - Leading beauty companies such as Proya, Mao Geping, and Shangmei continue to outperform, while Huaxi Biological and Fulejia are lagging behind [2][4]. - Proya reported a revenue of 5.362 billion yuan, a year-on-year increase of 7.21%, and a net profit of 799 million yuan, up 13.8%. However, its main brand experienced a slight revenue decline of 0.08% [5][6]. - Mao Geping, known as the "first stock of high-end domestic beauty," achieved a revenue of 2.588 billion yuan, with a net profit of 670 million yuan, both showing over 30% growth. The gross margin reached 84.2% [6]. - Shangmei's revenue was 4.108 billion yuan, growing 17.3%, with a net profit of 556 million yuan, up 34.7%. The "newpage" brand saw a revenue increase of 146.5% [6][7]. - Juzhi Biological reported a revenue of 3.113 billion yuan, a 22.5% increase, and a net profit of 1.182 billion yuan, up 20.2%, although growth rates have slowed compared to the previous year [7]. Group 2: Underperforming Companies - Huaxi Biological, referred to as the "first stock of hyaluronic acid," reported a revenue decline of 19.57% to 2.261 billion yuan and a net profit drop of 35.38% to 221 million yuan, marking its worst interim report since listing [9]. - The decline in Huaxi's revenue is attributed to a significant drop in its functional skincare business, which saw a 31.62% year-on-year decrease in 2024 [9]. - Fulejia's revenue was 863 million yuan, down 8.15%, with a net profit of 230 million yuan, a decrease of 32.54%. The company faced a substantial increase in sales expenses, which rose by 39.56% [11][12]. Group 3: Second-Tier Companies - Second-tier beauty companies such as Shanghai Jahwa, Marubi, and Shuiyang are showing improved performance [13][14]. - Shanghai Jahwa achieved a revenue of 3.478 billion yuan, a 4.75% increase, and a net profit of 266 million yuan, up 11.66%, attributed to online channel growth [15]. - Marubi reported a revenue of 1.769 billion yuan, a 30.83% increase, but its net profit only grew by 5.21%, indicating a potential profitability challenge [15][16]. - Shuiyang's revenue reached 2.5 billion yuan, a 9.02% increase, with a net profit of 123 million yuan, up 16.54%. The company is transitioning to a global high-end beauty brand management model [16].

Core Insights - Huaxi Biological Technology Co., Ltd. reported its worst interim results since its listing, with a revenue of 2.261 billion yuan, a year-on-year decline of 19.57%, and a net profit of 221 million yuan, down 35.38% [2][3] Business Performance - The three main business segments of Huaxi Biological all experienced declines: the skin science innovation transformation business fell by 33.97% to 912 million yuan, accounting for 40.36% of total revenue; the raw materials business saw a slight decrease of 0.58% to 626 million yuan, making up 27.7% of revenue; and the medical terminal business dropped by 9.44% to 673 million yuan, representing 29.77% of revenue [3][9] - The company faced significant profit pressure due to credit impairment, asset impairment, and personnel optimization, with a total of 48.37 million yuan in impairment losses reported in the second quarter [3] Management Issues - Internal management problems have surfaced, including a financial fraud scandal involving a former marketing director, which has led to public disputes and allegations of financial misconduct [5] - The company has undergone significant management changes, with a focus on reforming its operational structure and reducing reliance on external management [6][7] Strategic Reforms - Founder Zhao Yan returned to the company to implement major reforms, including a crackdown on corruption and a shift towards hiring entrepreneurial talent for management positions [6][7] - Huaxi Biological is concentrating its resources on high-margin core segments, specifically raw materials and medical terminal businesses, which contributed over 57% of its main business revenue in the first half of 2025 [9][10] Research and Development Focus - The company has reduced its R&D projects significantly, focusing on raw materials and medical terminal businesses, while sales expenses decreased by 31.44% to 808 million yuan [8] - Despite the challenges, there are signs of marginal recovery, with a net profit of 119 million yuan in the second quarter of 2025, marking a year-on-year increase of 20.89% [8]

Group 1 - The controlling shareholder of Huaxi Biological Technology Co., Ltd., Huaxi Xinyu Investment Co., Ltd., plans to increase its shareholding in the company, with a minimum investment of RMB 200 million and a maximum of RMB 300 million, starting from August 8, 2025, for a period of six months [2] - As of August 29, 2025, Huaxi Xinyu has already acquired 2,117,690 shares, representing 0.44% of the total share capital, with a total investment amounting to RMB 122,326,228.05, exceeding 50% of the lower limit of the planned investment [2] - The share buyback plan is still ongoing, and Huaxi Xinyu will continue to purchase shares according to the established plan [2][5] Group 2 - The announcement confirms that the shareholding increase will not lead to a change in the controlling shareholder or actual controller of the company [4] - The company will continue to monitor the progress of the share buyback and fulfill its information disclosure obligations as required by the China Securities Regulatory Commission and the Shanghai Stock Exchange [5]

Core Viewpoint - The controlling shareholder of Huaxi Biotechnology Co., Ltd., Huaxi Xinyu Investment Co., Ltd., has initiated a share buyback plan, expressing confidence in the company's future development and long-term investment value [1] Group 1: Buyback Plan Details - The buyback plan will commence on August 8, 2025, and will last for six months, with a planned investment of no less than RMB 200 million and no more than RMB 300 million [1] - The buyback will not exceed 1% of the company's total share capital, and the purchase price will not exceed RMB 70 per share [1] Group 2: Initial Buyback Execution - On August 27 and 28, 2025, Huaxi Xinyu purchased a total of 1,533,569 shares, representing approximately 0.32% of the company's total share capital, for a total amount of RMB 88,683,021.15 [2][5] - The shares were acquired through the Shanghai Stock Exchange's centralized bidding system [5] Group 3: Shareholder Information - Huaxi Xinyu Investment Co., Ltd. is the controlling shareholder, holding 283,500,000 shares, which accounts for 59.17% of the total share capital [3][5] - The company has identified consistent action among shareholders, including the actual controller and chairman, Zhao Yan, who holds a significant stake through various entities [3][4] Group 4: Future Buyback Plans - The company will continue to execute the buyback plan using self-owned or raised funds, with ongoing monitoring of the buyback progress [5][6]

Core Viewpoint - Domestic beauty brands are collectively facing a slowdown after years of rapid growth, as evidenced by Beitaini's significant revenue and profit declines in the first half of 2025 [1] Financial Performance - Beitaini reported a revenue of 2.372 billion yuan and a net profit of 247 million yuan for the first half of 2025, representing year-on-year declines of 15.43% and 49.01% respectively [1] - The company's second-quarter revenue was 1.423 billion yuan, down 16.67% year-on-year, marking its first loss during the "618 shopping festival" in four years [2] Marketing Strategy Adjustments - Beitaini is controlling its promotional spending, with sales expenses for the first half of 2025 at 1.285 billion yuan, a modest increase of 0.6% year-on-year, but a slowdown of 15.81 percentage points compared to the same period in 2024 [2] - The company has shifted its focus from low-efficiency promotions to content marketing, user education, and precise conversion strategies, which has improved gross margins and operating cash flow [6] Product Category Performance - Beitaini has seen declines across various product categories, particularly in medical device products, which generated 116 million yuan in revenue for the first half of 2025, a drop of over 50% year-on-year [6] - The company has reduced resource allocation for medical device products and is concentrating more on core skincare categories and high-growth segments [8] Growth Potential - Beitaini's anti-aging skincare brand, Aikeman, has transitioned from beauty salons to e-commerce, achieving over 90% year-on-year growth with revenue of 51 million yuan in the first half of 2025 [8][9]

Summary of Key Points Core Viewpoint - The controlling shareholder of Huaxi Biological, Huaxi Xinyu Investment Co., Ltd., is actively increasing its stake in the company, indicating confidence in the company's future performance and potential growth [1]. Group 1: Buyback Plan Details - Buyback Entity: Controlling shareholder Huaxi Xinyu Investment Co., Ltd. [1] - Buyback Period: From August 8, 2025, to February 7, 2026 (6 months) [1] - Total Investment Amount: Between 200 million to 300 million RMB [1] - Maximum Buyback Proportion: Not exceeding 1% of total share capital [1] - Maximum Buyback Price: Not exceeding 70 RMB per share [1] Group 2: Latest Buyback Progress - Implementation Dates: August 27-29, 2025 [1] - Shares Acquired: 2.1177 million shares, accounting for 0.44% of total share capital [1] - Total Investment Amount: 122 million RMB [1] - Progress Completion: Exceeded 50% of the lower limit of the buyback plan of 200 million RMB [1] Group 3: Shareholding Situation - Shareholding Before Buyback: 283.5 million shares, representing 58.86% [1] - Total Shares Held by Concerted Actors: 285 million shares, representing 59.17% [1] - Actual Controller: Chairman and General Manager Zhao Yan [1] Group 4: Future Arrangements - The buyback plan is not yet completed and will continue as planned [1] - Future buybacks will be financed through self-owned or raised funds [1]

证券代码：688363 证券简称：华熙生物 公告编号：2025-033 华熙生物科技股份有限公司 关于控股股东增持股份进展暨增持金额过半的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 已披露增持计划情况：华熙生物科技股份有限公司（以下简称"华熙生 物""公司"）的控股股东华熙昕宇投资有限公司（以下简称"华熙昕宇"） 基于对公司未来发展的信心和长期投资价值认可，计划自 2025 年 8 月 8 日起的 括但不限于集中竞价、大宗交易等）增持公司股份，增持金额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），增持股份比例不超过公司总股本 1%， 增持股票价格不超过 70 元/股。具体内容详见公司于 2025 年 8 月 8 日在上海证 券交易所网站（www.sse.com.cn）披露的《华熙生物科技股份有限公司关于控股 股东增持公司股份计划公告》（公告编号：2025-028）。 ? 增持计划的实施情况：截至 2025 年 8 月 29 日，华熙昕宇通过上海证券 交易所交易系统以集中竞价 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-033 华熙生物科技股份有限公司 关于控股股东增持股份进展暨增持金额过半的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：华熙生物科技股份有限公司（以下简称"华熙生 物""公司"）的控股股东华熙昕宇投资有限公司（以下简称"华熙昕宇"） 基于对公司未来发展的信心和长期投资价值认可，计划自 2025 年 8 月 8 日起的 6 个月内，使用自有资金或自筹资金，通过上海证券交易所系统允许的方式（包 括但不限于集中竞价、大宗交易等）增持公司股份，增持金额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），增持股份比例不超过公司总股本 1%， 增持股票价格不超过 70 元/股。具体内容详见公司于 2025 年 8 月 8 日在上海证 券交易所网站（www.sse.com.cn）披露的《华熙生物科技股份有限公司关于控股 股东增持公司股份计划公告》（公告编号：2025-028）。 增持计划的实施情况：截至 2025 年 ...

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 56.57 CNY [4][10]. Core Insights - The company focuses on big product lines and streamlining its main brand SKU strategy to drive continuous improvement in gross margin. However, the significant decline in offline channels in 1H25 has impacted main brand growth. There are expectations for new products to expand the consumer base and improve operational efficiency on platforms like Douyin [2][10]. - In 1H25, the company reported total revenue of 2.372 billion CNY, a year-on-year decline of 15.43%, and a net profit attributable to the parent company of 247 million CNY, down 49.0% year-on-year. The gross margin improved to 76.0%, up 3.42 percentage points, attributed to a focus on big products and reduced promotions [10][11]. - The company has adjusted its EPS forecasts for 2025 and 2026 to 1.12 CNY and 1.49 CNY, respectively, reflecting the impact of short-term offline channel adjustments and product line streamlining [10][11]. Financial Summary - For 2023A, the total revenue is projected at 5.522 billion CNY, with a year-on-year growth of 10.1%. The net profit attributable to the parent company is expected to be 757 million CNY, down 28.0% [3][11]. - The company’s gross margin is expected to improve to 75.3% in 2025E, with a net profit margin of 8.6% [11]. - The company’s total assets are projected to reach 8.456 billion CNY by 2025E, with total liabilities of 1.936 billion CNY [11]. Market Performance - The stock has a 52-week price range of 39.34 CNY to 70.30 CNY, with a total market capitalization of 19.871 billion CNY [5][10]. - The stock has shown an absolute increase of 14% over the past 12 months, although it has underperformed relative to the index by 41% [9][10].